drugset / Trial / NCT03549689
Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, randomized pilot study to assess the effect on bone mineral density (BMD) of a switch from a tenofovir alafenamide-containing antiretroviral regimen to dolutegravir/lamivudine vs. a continuation of the tenofovir alafenamide-containing regimen.
Timeline
- Start
- 2019-08-01
- Primary completion
- 2021-07-01
- Completion
- 2021-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dolutegravir | Other / unclassified | 50 mg | Oral |
| Subject | Lamivudine | Other / unclassified | 300 mg | Oral |
| Comparator | tenofovir alafenamide | Small molecule | — | — |